Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective ,multicenter, cohort trial to evaluate the efficacy and safety of telaprevir versus simeprevir based triple therapy in patients with hepatitis C after living donor liver transplantation

Trial Profile

A retrospective ,multicenter, cohort trial to evaluate the efficacy and safety of telaprevir versus simeprevir based triple therapy in patients with hepatitis C after living donor liver transplantation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simeprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use

Most Recent Events

  • 01 Dec 2016 Results assessing efficacy and safety published in the Hepatology Research.
  • 18 Apr 2016 New trial record
  • 01 Mar 2016 Results published in the Hepatology Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top